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PERSPECTIVES IN CLINICAL NEPHROLOGY
Thrombosis and hemostasis in renal disease
Normal hemostasis is initiated by damage of the vessel wall with
exposure of subendothelial structures to flowing blood and results
in the formation of a solid hemostatic plug. The first step of this
hemostatic response involves platelet adherence to the subendo-
thelium [1—3]. The number of platelets available for this process
(Fig. 1A) is determined by platelet count. It is, however, even
more dependent on red blood cell-mediated transport of circulat-
ing platelets towards the vessel wall [1—3]. This transport is
enhanced at higher hematocrit, increased blood flow and with less
deformable or larger red blood cells [3—5]. The adhesion of
platelets to the site of injury is initially mediated by interactions
between specific platelet receptors and adhesive proteins in or
deposited on the subendothelium [61. The quality of the platelet
adhesion, however, depends strongly on subsequent platelet acti-
vation. Platelet activation is initiated by stimuli present or formed
at the vessel wall but is sustained by products (for example,
thromboxane and ADP) released from activated platelets them-
selves [6]. Platelet activation leads to expression of additional
receptors on platelet membranes which support platelet interac-
tion with subendothelium [7]. Most importantly, however, these
receptors mediate platelet-platelet interactions resulting in aggre-
gate formation.
The main adhesive protein von Willebrand factor (vWF)
present in the subendothelium or deposited there from the
circulation is essential for initial platelet adhesion by binding to
glycoprotein lb constitutively present at platelet membranes [8, 9].
With fibrinogen, vWF is also able to interlink activated platelets
into aggregates by serving as ligand of glycoprotein Jib-lila on
activated platelets (Fig. 1B) [10]. Collagen, present in the suben-
dothelium, not only supports initial adhesion via platelet glyco-
protein Ia-ha, but is also an important stimulus of platelet
aggregation by mobilizing glycoprotein IIb-IIIa at the platelet
surface [6]. Normal hemostasis also involves initiation of coagu-
lation at sites of vessel wall injury which starts with activation of
factor VII from flowing blood by tissue factor present in the vessel
wall. The key products of the coagulation cascade are thrombin
and fibrinogen. Thrombin proteolytically converts fibrinogen to
insoluble fibrin, which in its turn activates factor XIII that causes
cross linking of fibrin fibers (Fig. 1C) [11]. With collagen, throm-
bin is also a main stimulus of platelet activation and aggregation
[6]. Fibrin is able to stabilize platelet aggregates and other cellular
elements in a shear stress resistant network. Pathological throm-
bin formation is prevented by natural anticoagulant systems, of
which antithrombin III and the vitamin K-dependent protein C
system are the most important. In addition to these anticoagulant
systems the fibrinolytic system generates plasmin by the action of
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tissue plasminogen activator on plasminogen. Plasmin dissolves
the fibrin clot and thus prevents pathological thrombus formation.
The fibrinolytic system is closely regulated by inhibitors of plas-
minogen and plasmin, such as a2-antiplasmin, cs2-macroglobulin,
and Cl-activator.
The formation of the normal hemostatic plug therefore re-
quires both coagulation and platelet dependent processes. Defects
in either process will result in bleeding complications. On the
other hand abnormally enhanced hemostasis with flow-dislodged
thrombus products, or hemostasis not adequately localized on
injured sites, will result in thromboembolic complications. The
presence of renal disease has been associated with profound
clinical effects on hemostasis ranging from thrombosis (in the case
of nephrosis) to bleeding complications (in uremia). The intro-
duction of perfusion chambers in which anticoagulated blood can
be exposed to models of injured vessel wall (such as matrix of
cultured endothelial cell or isolated adhesive proteins) has cre-
ated the possibility to simulate flow-dependent hemostatic and
thrombotic processes in vitro. The use of patient blood in these
systems has resulted in better understanding of the pathophysiol-
ogy of hemostasis. This review will discuss current views on
hemostasis in patients with nephrotic syndrome, renal failure and
renal transplants, and the implications for therapy.
Nephrotic syndrome
Thromboembolic complications are a major threat to the
nephrotic patient. Deep vein thrombosis, pulmonary embolism
and renal vein thrombosis occur most often, but thrombosis of
peripheral and coronary arteries has been described as well
[12—17]. The incidence has been estimated at approximately 35%
of all patients [12]. Patients with membranous glomerulopathy
and heavy proteinuria run the highest risk [16—18]. A 19%
incidence of abnormal ventilation/perfusion scans found in adult
nephrotic patients without any clinical evidence of pulmonary
thrombosis, suggests that the real incidence of thromboembolism
in the nephrotic syndrome may even be higher [19]. Renal vein
thrombosis is also a frequent complication of the nephrotic
syndrome. It is probably asymptomatic in most cases, but it may
present itself by flank pain, macroscopic hematuria or by unex-
plained rapid detonation of renal function [12, 13, 16, 17].
Most studies on the pre-thrombotic state in nephrosis have
focused attention on the presence of platelet abnormalities that
may indicate enhanced platelet-vessel wall interaction. Several
factors supporting increased initial platelet adhesion to the in-
jured vessel wall have been identified in nephrosis. Thrombocy-
tosis, increasing platelet availability at the vessel wall, is often
present in nephrosis [15}. Decreased red blood cell deformability
and increased von Willebrand factor (vWF) are also present in
nephrotic patients [20]. These are conditions associated respec-
tively with increased platelet transport towards the vessel wall and
with increased platelet adhesion [5, 8]. Thrombosis is further
determined by platelet aggregate formation on top of adherent
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Fig. 1. Schematic view of normal hemostasis, A. Red blood cells (RBC) favor platelet transport towards the vessel wall; B. platelets adhere to vWF by
binding to the glycoprotein (GP) lb and jib-lila receptor. Subsequent platelet activation results in recruitment of GPIIbIIIa on the platelet membrane.
Platelet aggregates develop as circulating vWF and fibrinogen bind to GPT1blI1a. C. Thrombin activation by tissue factor-induced coagulation causes
formation of a fibrin network, which consolidates the platelet-plug. Fibrinopeptide A (FPA) is formed during fibrinogen-fibrin transformation.
platelets. In vitro studies in patients with a nephrotic syndrome
have shown marked platelet hyperaggregability [20—24]. This
hyperaggregability probably has a multifactorial pathogenesis, and
is associated with low serum albumin, hypercholcsterolemia and
hyperfibrinogenemia [23, 24]. Few studies have dealt with the
mechanism of hyperaggregability and with the relevance of these
associated changes. Hypoalbuminemia increases the availability of
free, normally albumin bound, arachidonic acid resulting in
increased formation of the proaggregatory agent thromboxane A2
in platelets, which sustains platelet aggregation [21, 22, 25, 26].
However, platelet hyperaggregability to other stimuli, such as
ADP, collagen and ristocetin, could not be related to hypoalbu-
minemia [23, 24]. This suggests the presence of additional plasma
factor(s) determining the in vitro hyperaggregability. Markedly
elevated levels of LDL cholesterol in the nephrotic patient [27]
may increase in vitro platelet aggregation, as was observed in
patients with familial hypercholesterolemia [28]. In agreement
with this hypothesis, 12 weeks of lipid lowering treatment resulted
in disappearance of the spontaneous hyperaggregability in ne-
phrotic subjects. However, the increased aggregation upon arachi-
donic acid persisted in these experiments [29]. Hyperfibrinogen-
emia, invariably present in the nephrotic patient, is a third plasma
factor that may cause platelet hyperaggregability. Increasing
concentrations of fibrinogen, a ligand of glyeoprotein Jib-lila
receptors on activated platelets (Fig. 1), indeed enhanced spon-
taneous platelet aggregation in stirred platelet-rich suspensions
[20]; moreover, ADP-stimulated platelet aggregability was corre-
lated with the plasma fibrinogen in nephrotic subjects [241. Studies
on isolated platelets in order to identify an intrinsic platelet
abnormality are scarce. One study reported on decreased negative
surface charge of isolated nephrotic platelets with possible in-
creased binding of vWF to glycoprotein lb [30].
The main determinant of in vivo platelet-vessel wall interaction
is flow. Thus far, this factor has not been taken into account in
evaluating platelet-vessel wall interaction in the nephrotic syn-
drome. Therefore, we recently performed perfusion studies with
nephrotic blood under well-defined flow conditions [20]. Two
models of an injured vessel wall, namely de-endothelialized
human umbilical artery segments or sprayed collagen type 1, were
used (Fig. 2). In these studies normal platelet adhesion and only
a modest increase in the formation of aggregates were observed
[20]. The increased risk of acute thromboembolic complications in
nephrosis is therefore not adequately explained by a strongly
enhanced platelet-vessel wall interaction, The expected increase
in platelet adherence by high vWF, decreased red blood cell
deformability and platelet hyperaggregation is possibly neutral-
ized by fibrinogen binding to glycoprotein JIb-lIla, thereby inter-
fering with vWF-glycoprotein Jib-lila mediated adhesive pro-
cesses. In contrast, under low shear stress conditions, such as in
suspensions, fibrinogen binding may, however, be strong enough
to enhance platelet aggregation. Addition of extra fibrinogen to
control blood (with normal vWF levels) inhibited platelet adhe-
sion under flow conditions, but also enhanced the aggregatory
response of platelets in platelet rich plasma in an aggregometer
[20].
These data challenge the concept of increased in vivo platelet-
vessel wall interaction in nephrotie syndrome as the predominant
thrombotic risk factor. However, this does not imply that in-
creased platelet activation may not play a role at all in the
prethrombotic state of nephrosis in vivo. The models of injured
vessel wall used in the perfusion studies do not take into account
modifications of the vessel wall that may occur in the nephrotic
syndrome in vivo. Nephrotic patients have high levels of LDI,,
which are probably enriched with lysolecithiri [27, 31]. Such
modified LDL is toxic particularly for the endothelium, and leads
to impaired nitric oxide production [32], Recently, nitric oxide has
been advanced as an inhibitor of platelet adhesion [33]. It is
therefore possible that some patients with nephrotic syndrome
have decreased nitric oxide produetion which subsequently may
lead to increased platelet-vessel wall interaction in vivo. Studies
are currently being performed by our laboratory to test this
hypothesis. The presence of increased in vivo platelet activation is
supported by levels of the platelet release product -thrombo-
globulin [24, 33—38], which may be increased in nephrotic patients
even when discarding patients with decreased clearance of
/3-thrombogiobuiin due to impaired renal function [24, 38].
Increased formation of fibrin may also cause the pre-throm-
botie state of the nephrotie syndrome. To evaluate the contribu-
tion of fibrin formation to the thrombotic risk in these patients,
blood of these patients was circulated over tissue factor-rich
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matrix of cultured endothelial cells. Local thrombin formation at
this matrix via activation of the extrinsic coagulation pathway,
allows the study of platelet adhesion, together with thrombin
dependent platelet activation, and fibrin formation, all at the same
surface [39]. We found that control blood tends to form substan-
tial fibrin networks only at lower, venous shear rates, whereas
nephrotic blood circulating in this system forms extensive fibrin
depositions, even at high flow rates [20}. The increased fibriri
generation was not associated with increased fragment 1, 2
formation, which is cleaved from prothrombin during its activa-
tion (Fig. 1C) [20]. This suggests that activation of the coagulation
cascade was not enhanced in these patients. Therefore, in these
patients a more effective fibrinogen-fibrin transition seems an
explanation for the massive fibrin depositions. The obvious cause
is increased substrate availability. We found a strong correlation
between fibrin deposition and hyperfibibrinogenemia, which thus
constitutes an important risk factor for thrombus formation, In
agreement, the addition of fibrinogen to control perfusates also
resulted in increased fibrin depositions [20]. Increased fibrin
deposition in these perfusion studies was associated with de-
creased platelet adhesion directly to the subendothelium (Fig. 3),
illustrating the more clotting dependent hemostasis in nephrotic
patients.
Increased fibrin depositions may not only be caused by higher
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Fig. 2. Schematic drawing of the peifusion system. (1.) Inverted de-endothelialized arteries (indicated by the grey box) are mounted on a rod (A). Blood
is subsequently (re)perfused from right to the left. (2.) Collagen, or endothelial cell matrices on coverslips (B) are mounted on a perspex knob and placed
in a rectangular perfusion chamber. Hereafter blood is perfused from right to the left during 3 to 10 minutes. Shear rates vary between 300/second and
1300/second. After perfusion the arteries and coverslips are fixed and embedded in epon. Platelet adhesion and aggregate formation is evaluated by light
microscopy. (3.) Example of en face morphology (top) and in cross section (bottom) of platelet aggregates (a) and flbrin (F) depositions on matrices
of umbilical endothelial cells.
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Fig. 3. Platelet adhesion, aggregate formation
and fibrin depositions after peifusion of nephrotic
blood over tissue factor-rich endothelial cell
matrix. Symbols are (LI) nephrotic subjects; (I)
control subjects; # P <0.05, ## P < 0.01
compared to control subjects. Despite increased
platelet aggregation in Vitro, platelet adhesion
and aggregate formation was decreased in
nephrotic subjects while fibrin depositions were
markedly enhanced (adapted, with permission,
from [20]).
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levels of fibrinogen, but also be formed in the presence of
increased thrombin formation and during less effective thrombin
inhibition. Increased thrombin formation may be caused by
increased levels of clotting factors V and VIII, which are often
found in the nephrotic syndrome [15, 40]. Less effective inhibition
of the coagulation cascade will also stimulate thrombin formation
and is an accepted cause of increased thromboembolic risk.
Studies on plasma levels of the natural occurring anticoagulants
have yielded conflicting results in nephrosis. Though increased
levels of plasma protein C, which inactivates factors V and VIII,
and its co-factor S are reported in most studies, free (active)
protein may be S reduced [41—44]. Finally, less effective inhibition
of thrombin by antithrombin III deficiency will result in increased
coagulant activity and subsequent fibrin formation. Several studies
have reported decreased levels of antithrombin III in nephrotic
patients [45—47], in particular in the presence of gross proteinuria
[45]. However, normal or increased levels of antithrombin III
have also been found [15, 48, 49] and a2-macroglobulin, as an
alternative inhibitor of thrombin, is often increased in nephrosis
[48]. Nevertheless, although data on increased thrombin forma-
tion and thrombin activity are sometimes conflicting in nephrosis,
it is very likely that these mechanisms do occur in a subset of
nephrotic patients. This certainly will then accelerate fibrinogen-
induced fibrin formation and contribute to the thrombotic risk of
these patients.
In vivo fibrin deposition in nephrotic subjects is also suggested by
elevated levels of circulating fibrinopeptide A and of high molecular
weight fibrin complexes [38, 50, 51]. Fibrin networks promote the
inclusion of red blood cells and other cellular elements, and thus the
formation of a mixed thrombus [2]. Furthermore, fibrin depositions
are also present in atherosclerotic lesions, and are proposed to
contribute to atherosclerosis by causing endothelial cell disorganiza-
tion, by stimulating the proliferation of vascular smooth muscle cells,
and by providing an adsorptive face for LDL accumulation [52, 53].
In nephrotic patients elevated fibrinogen in renal vein blood cone-
lates with intraglomerular fibrin depositions, and may contribute to
the development of glomerular injury [54]. Finally, hyperfibrinoge-
mia increases blood viscosity [55] and red blood cell aggregation [56,
571 in nephrosis. These hemorrheologic changes decrease organ
blood flow and also contribute to the formation of a mixed thrombus.
The thrombotic risk of nephrosis is further enhanced by de-
creased fibrinolytic activity. A decreased fibrinolysis in nephrotic
patients may be caused by decreased levels of plasminogen [48],
which has been shown to correlate with the magnitude of the
proteinuria [58]. Increased levels of a2-antiplasmin in some
patients will further contribute to the hypofibrinolytic state by
inhibiting plasmin and interfering with its binding to fibrin [59].
Recently, hypoalbuminemia itself has also been identified as a
possible factor causing hypofibrinolysis. Albumin appears to be a
cofactor for the binding of plasminogen to fibrin and the subse-
quent interaction with tissue plasminogen activator [60]. Patients
with nephrotic syndrome have elevated levels of lipoprotein (a) as
well [Lp(a)j [61—63], which has a close structural similarity to
plasminogen [64]. Indeed, in vitro studies have shown that Lp(a)
can compete with plasminogen for its binding to fibrinogen or
fibrin and may inhibit the fibrin-dependent enhancement of
plasminogen activation by tissue plasminogen activator (t-PA)
[65, 66]. The possible contribution of Lp(a) to the thrombotic risk
in nephrotic subjects has not yet been determined.
Table 1. Thrombotic abnormalities in the nephrotic syndrome
(1) Increased in vitro platelet hyperaggregability
(2) Normal platelet adhesion and only slightly enhanced platelet
aggregation under flow conditions
(3) Hyperfibrinogenemia
(4) Increased fibrinogen-fibrin transition, secondary to high plasma
levels of fibrinogen
(5) Sometimes decreased antithrombin III
(6) Decreased fibrinolysis
Therapy for nephrotic syndrome
In the clinical setting matters are more complicated by the facts
that neither platelet aggregation nor levels of antithrombin III,
clotting factors or even fibrinogen have a clear predictive value in
defining patients at risk for thromboembolism 118] and therefore
eligible for treatment. The consequence of the in vitro observa-
tions (Table 1), however, is that in most cases therapy should be
directed at coagulation, such as by enhancement of thrombin
inhibition, decreasing thrombin formation and reducing fibrino-
gen, or by improving fibrinolysis, rather than directed at the
inhibition of platelet aggregation.
(1) Enhancement of thrombin inhibition. Heparin exerts its
anticoagulant effect by forming a complex with antithrombin III
and increasing the rate at which antithrombin III inactivates
thrombin. Usually higher dosages of heparin are needed to
achieve adequate anticoagulation in nephrotic patients [67, 68].
This may not only be caused by decreased antithrombin III levels,
but may also relate to alterations in surface charge of heparin in
nephrotic patients [68]. The usefulness of heparin in nephrotic
syndrome has also been questioned for another reason: in ne-
phrotic patients increased levels of c2-macroglobulin probably act
as an inhibitor of thrombin [47]. Heparin inhibits the binding of
a2-macroglobulin to thrombin, which in the presence of decreased
levels of antithrombin III theoretically may result in a net
thrombogenic effect [47]. Nevertheless, heparin is the only drug
that can cause rapid anticoagulation in a patient with a manifest
thromboembolic complication, and it should be stressed that the
possible thrombotic effects of heparin have not been confirmed in
clinical studies.
(2) Decreasing thrombin formation. Coumarin derivatives inter-
fere with factor VII-activated thrombin formation. Since protein
binding of these drugs is >99%, coumarin derivatives have
different pharmacokinetics in the presence of hypoalbuminemia.
Coumarin derivatives are probably the best treatment option to
prevent or treat thromboembolic complications [16]. This also
applies to renal vein thrombosis. There is no advantage of
thrombectomy or fibrinolytic therapy in this complication over
administration of coumarins [16, 17]. It is not clear how long
anticoagulation should be continued. For practical purposes it
seems prudent to anticoagulate a nephrotic patient after a throm-
boembolic event for as long as proteinuria persists [131. As
mentioned before, the incidence of thromboembolic complica-
tions is highest in membranous glomerulopathy [16, 181, where
they are associated with a high mortality [69, 701. After analyzing
the risks of anticoagulation versus those of thromboembolism in
the nephrotic syndrome, Bellow and Atkins advocate prophylactic
anticoagulation in patients with membranous nephropathy [71].
Prospective studies on parameters of thrombin generation to-
gether with parameters of the actual fibrinogen-fibrin transition
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may perhaps enable us to better define the patients at risk for
thromboembolism.
(3) Decreasing fibrinogen levels. At present no specific fibrinogen
lowering drugs are available for clinical use. Fibrates have been
shown to decrease fibrinogen by 20 to 40% in hyperlipidemic
subjects [72], but whether this is also the case in nephrotic subjects
remains to be established. Hyperfibrinogemia correlates directly
with proteinuria [73], which suggests that antiproteinuric therapy
with converting enzyme inhibitors or NSAIDs may have a bene-
ficial effect on the high fibrinogen levels in nephrotic syndrome
and may decrease fibrinogen-fibrin transition. Again, clinical data
on this possibility are lacking.
(4) Improving fibrinolysis. As discussed above, albumin acts as a
cofactor for the binding of plasminogen to fibrin [601, which
implies that antiproteinuric treatment may also improve fibrinol-
ysis. Interestingly, it was recently shown that the increased levels
of Lp(a) in nephrotic patients can be reduced by administration of
converting enzyme inhibitors [74, 75].
Chronic renal failure
Patients with chronic renal failure may present with a bleeding
tendency as well as with thrombotic complications. A bleeding
diathesis in patients with renal failure was already recognized as
early as the 18th century [76]. The clinical manifestations of
bleeding are often mild and include symptoms such as ecchynio-
ses, purpura, epistaxis and gingival bleeding. Severe bleeding
complications such as hemopericard or cerebral hemorrhages
occurred only before dialysis became available as a standard
treatment. Excessive bleeding following trauma and blood loss
during surgery, however, are still common [reviewed in 76, 77]. On
the other hand, uremic patients also have an increased incidence
of thrombotic complications such as ischemic heart attacks, stroke
and thromboses of arteriovenous fistulae [78].
Bleeding symptoms in uremic patients correlate best with
prolonged skin bleeding times and suggest a defect in primary
(platelet dependent) hemostasis [79], known for a long time as
uremic thrombocytopathy. As mentioned earlier, the first step in
hemostasis is platelet adhesion to exposed subendothelial tissue.
Platelet count, number and deformability of red blood cells and
flow determine the transport of platelets to the vessel wall.
Platelet counts in renal failure are generally normal in renal
failure [80], but anemia is a major contributor to the bleeding
tendency because it decreases availability of platelets near the
injured vessel wall [81]. As soon as the anemia is corrected by
blood transfusion [82, 83] or by erythropoietin treatment [84],
bleeding symptoms decrease and bleeding times shorten. How-
ever, anemia is not the only reason, since correction of the
hematocrit in most cases only partially corrects bleeding time [83].
The fact that platelet adhesion in normal blood with artificially
reduced hematocrit still significantly exceeds that in uremic blood
at a corresponding hematocrit [81] clearly suggests an additional
hemostatic defect(s) in uremia.
The actual platelet adhesion to the injured vessel wall is
determined by adhesive proteins in plasma or bound to the vessel
wall (such as vWF), platelet receptors, and platelet function itself
(Fig. 1). Binding of vWF to the platelet glycoprotein lb as well as
glycoprotein lib-Illa receptor is essential for normal adherence
[8]. The binding of vWF to glycoprotein lb is intact in uremia
[85—87], and vWF appears to be functionally and structurally
normal [87—90]. Levels of vWF are usually increased in uremia
[87—90], and this certainly does not favor an adhesion defect.
However, there are indications for a functional defect in the
interaction of vWF with glycoprotein lIb-Illa, which could con-
tribute to an adhesion defect at higher shear rates [85]. This
interaction is also important for platelet aggregation on adherent
platelets, which is the next step in the hemostatic process. Most
platelet aggregation studies in uremia have been performed by
means of in vitro aggregometery. However, normal, decreased, as
well as increased aggregation responses to ADP, collagen and
epinephrine have been reported [91—97]. Several abnormalities
have been suggested to be responsible for the intrinsic platelet
defect, including reduced platelet content of serotonin and aden-
osine diphosphate, elevated cAMP content, and a reduced capac-
ity to release thromboxane A2 and increase intracellular Ca
[91, 98—100]. However, the large variation in the methods used
and the variability in results suggest that further studies are
required. This is also of importance because these in vitro studies
are difficult to extrapolate to the in vivo situation where shear
forces play such a dominant role.
Recently, adhesion and aggregation in uremic blood have been
studied under similar flow conditions, as described in the previous
section for the nephrotic syndrome [81, 87]. Perfusion of blood
from uremic subjects over de-endothelialized artery segments at
standardized flows and at normalized hematocrit yielded similar
platelet adhesion as perfusion with control blood [87]. These
patients had elevated vWF levels, and when additional vWF was
added to control blood to similar levels as in the uremic patients
a clear adhesion defect became apparent in blood from uremic
patients [87]. Therefore, it appears that increased vWF levels in
these patients overcome a platelet adhesion defect. Platelet
adhesion was higher, but not normal, when normal platelets were
reconstituted in plasma from uremic patients [81]. This indicates
that, in addition to an intrinsic platelet defect, a plasma factor
contributes to the adhesion defect. We also found reduced
aggregate formation during perfusion of uremic blood over a
tissue factor rich matrix [101]. This aggregation defect was also
present during perfusions with platelets from control subjects
which were reconstituted in uremic plasma [101], lending further
support to the notion that a plasma factor in uremia inhibits
platelet-vessel wall and platelet-platelet interactions. Another
indication for the role of a plasma factor in the uremic bleeding
tendency was derived from perfusion studies with blood from
uremic patients treated with erythropoietin. Platelet adhesion and
aggregation in these patients improved after erythropoietin treat-
ment, even when the perfusates had been standardized for
hematocrit [102]. This effect was attributed to neutralization of
uremic toxins by red blood cells, or to less production of toxins by
better oxygenated tissues. Increased levels of parathormone have
also been proposed as a possible factor in the uremic bleeding
tendency, since parathormone inhibits platelet aggregation in vitro
[103].
Finally, attention has been drawn to the role of vessel wall
endothelium itself in the uremic bleeding tendency by the studies
of Remuzzi and colleagues [104, 105]. They demonstrated an
enhanced prostacyclin production by vascular tissue of uremic
patients. This metabolite of the arachidonic acid pathway is a
potent inhibitor of platelet aggregation in vitro. Recently, these
observations have gained impetus from the discovery that another
secretion product of the endothelium, nitric oxide, is also capable
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Table 2. Factors that contribute to the hemostatic defect in uremia
(1) Decreased platelet transport to the vessel wall, secondary to anemia
(2) Intrinsic platelet defect
(3) Defective binding of vWF to glycoprotein Ilbilla
(4) Uremic toxins (PTH, middle molecules)
(5) Increased production of NO and prostacyclin by the vessel wall
Table 3. Factors that contribute to the pre-thrombotic state of uremia
(1) Increased levels of vWF
(2) Hyperfibrinogenemia
(3) Increased thrombin formation(4) Sometimes decreased antithrombin Ill
(5) Activation of coagulation during hemodialysis
of inhibition of platelet adhesion under flow conditions [33]. It
was again Remuzzi et al who demonstrated that inhibition of
nitric oxide formation in a rat model of uremia completely
normalized the bleeding tendency in these rats [106]. Increased
intraplatelet levels of cGMP, the second messenger of nitric oxide,
in uremic patients lend further support for a role of nitric oxide in
the multifactorial platelet adhesion defect of uremia [107, 108].
Paradoxically, the platelet adhesion defect in uremia is accom-
panied by a pre-thrombotic state. Uremic subjects have higher
levels of fibrinogen while at the same time thrombin formation is
increased [109, 110]. In addition, antithrombin III may be de-
creased in some patients [110]. Subsequently increased in vivo
fibrinogen-fibrin transformation is reflected by increased fibrin-
opeptide A formation in these patients. Activation of coagulation
is even more prominent in uremic patients who are treated with
hemodialysis [109]. Uremic patients also have increased plasma
levels of Lp(a) [111], which may perhaps impair the fibrinolytic
system [65, 66]. Interestingly, Goldwasser et a! recently found
Lp(a) in hemodialysis patients to be predictive for occlusion of
vascular access [112].
The defects that may contribute to the bleeding tendency in
uremia have been summarized in Table 2. Most of the therapeutic
options in the bleeding tendency in uremia are summarized as
follows.
(1) Stimulation of platelet transport to the vessel wall. Red blood
cells are an important determinant of platelet transport to the
vessel wall. Reduction of bleeding time can therefore be achieved
by increasing the hematocrit over 30% by blood transfusion or
erythropoietin treatment [82—84].
(2) Stimulation of the adhesion of platelets to the subendothelium.
As discussed before, the vWF-mediated platelet adhesion to
subendothelium is probably intact in uremia. In agreement with
these experimental observations, the administration of desmo-
pressin acetate (DDAVP), which causes an increased release of
vWF from storage sites, has a beneficial effect on the bleeding
tendency. DDAVP, given as an intravenous infusion of 0.3 tg/kg,
can temporarily correct the prolonged bleeding time without
appreciable side-effects [88, 113]. However, DDAVP does not
increase vWF and improve bleeding tendency in all uremic
patients [114, 115]. Moreover, repeated doses of DDAVP lose
effectiveness due to depletion of vWF stores [107]. Cryoprecipi-
tates, which are rich in vWF and fibrinogen, have also been proven
to be effective in shortening the bleeding time in uremia [116—
118]. However, the possible transmission of HIV and hepatitis
viruses is a major concern.
(3) Removal of the plasma factor that inhibits platelet-vessel wall
interaction. Before hemodialysis became available, bleeding com-
plications were an almost invariable aspect of uremia. Removal of
a plasma "toxin" contributes to a large extent to the current
reduction of these complications in renal failure. Hemodialysis
and peritoneal dialysis are also accompanied by an improvement
of in vitro platelet function [91, 96, 119]. There are no differences
between efficient hemodialysis and peritoneal dialysis in inlprov-
ing the renal bleeding tendency [96]. As discussed before, increas-
ing the hematocrit may also have a beneficial effect on clearance
and/or production of uremic toxins that play a role in the
hemostatic defect.
(4 Improvement of the intrinsic platelet defect. Theoretically, this
could be achieved by platelet transfusions. However, reconstitu-
tion experiments showed at most a partial normalization of the
adhesion defect [81], while others could not find any improvement
in platelet-vessel wall interaction [93]. There are no data available
on the clinical usefulness of platelet transfusions in uremia.
(5) Removal of NO-.synthase products. Although not available
for clinical use yet, inhibitors of NO-synthase may prove to be
useful in alleviating the bleeding tendency of uremia in the near
future. It should be noted, however, that their clinical applicability
may be limited by side effects such as hypertension.
(6) Conjugated estrogens. Finally, administration of conjugated
estrogens has been reported to give a substantial reduction of
bleeding time for a prolonged (up to 14 days) period [120]. The
mechanism by which conjugated estrogens alter hcmostasis in
uremic patients is unkown. The effectiveness of this therapy is
offset by the hormonal side effects, particular in males.
It should be realized that the uremic platelet adhesion defect
may also have a protective effect on the thrombotic tendency
in these patients (Table 3). It is therefore possible that improve-
ment of the platelet defect, for example by more effective
hemodialysis treatment and the use of erythropoietin, may at the
same time lead to more thromboembolic complications. Compre-
hensive studies on this matter are lacking. However, these obser-
vations argue in favor of correcting the bleeding tendency of
uremia only when a normal hemostasis is required (such as during
surgery).
Renal transplantation
Deep venous thrombosis occurs with higher frequency among
patients undergoing renal transplantation than in patients of the
same age group undergoing other major operations [121]. Renal
vein thrombosis is found in 0.5 to 4% of the patients with a
transplant [122, 123]. It usually occurs in the first month post-
transplantation, and is thought to be secondary to surgical com-
plications. At later stages, when graft function has stabilized, its
development may be associated with the use of immunosuppres-
sive therapy, lower extremity venous thrombosis, or rejection. In
severe acute vascular rejection thrombosis is widespread and gives
rise to a large number of small infarcts in the cortex [124]. The
thrombosis may involve the main vessels, with eventual develop-
ment of total graft necrosis.
It has been suggested that cyclosporin may increase the throm-
botic risk in renal transplant recipients. Vanrenterghem et al [125]
in a retrospective study found an increased incidence of early
venous thromboembolism in cadaveric kidney recipients treated
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with cyclosporin. The most frequent thromboembolic complica-
tion was pulmonasy embolism. An increased incidence of renal
vein thrombosis in cyclosporin treated patients has been reported
as well [122]. In addition, cyclosporin toxicity has been associated
with increased glomerular capillary thrombus formation [126].
Changes that would promote thrombus formation, such as in-
creased factor VIII and fibrinogen, as well as factors that protect
against thrombosis (increased ATIII and protein C levels) have
been reported in patients treated with cyclosporin [125, 127].
Cyclosporin enhances in vitro platelet aggregation and subsequent
thromboxane A2 release [128]. Cyclosporin may also increase
platelet aggregation by reduced prostacyclin production by the
vessel wall [129]. Finally, the recent discovery of cyclosporin as a
scavenger of nitric oxide (NO) [130], which is an inhibitor of
platelet adhesion, lends further support for a role of cyclosporin in
enhanced platelet-vessel wall interaction. However, the relevance
of these findings under flow conditions has not yet been estab-
lished. The importance of studies under flow conditions is under-
scored by the discrepancy between the in vitro platelet function
test and platelet-vessel wall interaction during flow in patients
with a nephrotic syndrome, and by a recent prospective trial which
showed reduced—instead of increased—incidence of thromboem-
bolic complications in cyclosporin-treated renal transplant pa-
tients compared to patients treated with azathioprine [1311.
Therefore, at present it is not possible to advise on the routine
prophylactic use of antiplatelet agents in cyclosporin-treated
allograft recipients.
Prophylactic use of OKT3 has also been associated with throm-
bosis and thrombotic microangiopathy in the graft [132]. Re-
cently, it was shown that administration of OKT3 in transplant
recipients resulted in thrombin activation and increased levels of
vWF [133]. In vitro studies demonstrated that the thrombin
activation was mediated by the cytokine TNF-a [133].
In patients with established thromboembolic complications
coumarins are the treatment of choice, with the caveat of hem-
orrhage from operative sites, In view of the absence of collateral
circulation and the association with allograft rupture, acute renal
allograft vein thrombosis always requires immediate surgical
intervention. In renal vein thrombosis secondary to lower extrem-
ity, venous thrombosis local thrombolytic therapy may be of use
[134].
Conclusion
Recognition of the dynamic interaction between flowing blood
and vessel wall as a main determinant of thrombus formation over
the last decade has expanded our insight into the abnormalities of
hemostasis and coagulation. Despite marked abnormalities in in
vitro platelet function, the pre-thrombotic state of patients with
nephrotic syndrome appears to be determined more by hyperfi-
brinogenemia-induced fibrin deposition rather than by increased
platelet-vessel wall interaction. Future research and therapy
should be extended towards this abnormality and should attempt
to delineate the fibrinogen-fibrin transition as predictor for
thromboembolic risk. Perfusion studies have also further estab-
lished the presence of a plasma factor (toxin) that inhibits
platelet-vessel wall interaction in chronic renal failure. Further-
more, the vessel wall itself may contribute to the hemostatic defect
by enhanced production of endothelium-derived relaxing factors,
such as NO and prostacyclin. This defect can be counteracted by
compensatory stimulation of vWF and by promotion of platelet
transport to the vessel wall by red blood cells. At the same time a
pre-thrombotic state is present in most uremic patients. The
consequences of amelioration of the platelet defect for the
thrombotic risk in uremic patients are not yet known. Cyclosporin
has been implicated as a thrombotic risk factor in renal transplant
patients by inducing increased platelet adhesion and aggregate
formation. However, the relevance of the in vitro platelet dysfunc-
tion observed during cyclosporin treatment for the in vivo situa-
tion still has to be established.
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